Next Article in Journal
Efficacy and Safety of Intravenous Chemotherapy during Intensive Treatment Phase in Patients with Newly Diagnosed Pulmonary Tuberculosis
Previous Article in Journal
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer—Towards Daily Practice
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
ARM
Volume 86
Issue 3
10.5603/ARM.2018.0023
arm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Guidelines

Recommendations for the Management of Tuberculosis in Children—KOMPASS TB. Part 1: Tuberculosis Prevention

by
Teresa Bielecka
1,
Ewa Augustynowicz-Kopeć
2,
Paweł Gonerko
3,
Paweł Gruszczyński
4,
Maria Korzeniewska-Koseła
5,
Maria Krasińska
6,
Katarzyna Krenke
1,*,
Joanna Lange
1,
Anna Pankowska
7,
Marek Popielarz
8,
Andrzej Pustkowski
9,
Joanna Stryczyńska-Kazubska
10 and
Zbigniew Doniec
11
1
Department of Pediatric Pneumonology and Allergy, Medical University of Warsaw, Warsaw, Poland
2
Department of Microbiology, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland
3
I Department of Pediatrics, Allergy and Pulmonology, Szczecin, Poland
4
Department of Microbiology of the Wielkopolska Center for Pulmonology and Thoracic Surgery of Eugenia and Janusz Zeyland, Poznań, Poland
5
Department of Tuberculosis Epidemiology and Surveillance, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland
6
I Department of Pediatric Lung Diseases and Tuberculosis of Mazowsze Center for Lung Diseases and Tuberculosis Treatment, Otwock, Poland
7
Department of Pediatric Respiratory Diseases, Center for Lung Diseases Treatment and Rehabilitation, Łódź, Poland
8
Pediatric Pulmonology Clinic, University Hospital of Lord’s Transfiguration, Poznań, Poland
9
Department of Allergy and Lung Diseases, Children’s Hospital Polanki, Gdańsk, Poland
10
Department of Health Prophylaxis, Poznań University of Medical Sciences and Infectious Diseases Ward, Specialized Mother and Child Healthcare Centre in Poznań, Poznań, Poland
11
Department of Pneumonology, Tuberculosis and Lung Diseases Research Institute, Regional Department in Rabka-Zdrój, Rabka-Zdrój, Poland
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Author to whom correspondence should be addressed.
Adv. Respir. Med. 2018, 86(3), 149-157; https://doi.org/10.5603/ARM.2018.0023
Submission received: 12 March 2018 / Revised: 20 June 2018 / Accepted: 20 June 2018 / Published: 30 June 2018

Abstract

Since the second half of the 20th century the incidence of tuberculosis has been declining in Poland. Despite this, current epidemiological data still support the need for the continued mass BCG vaccination in Poland in the near future. Apart from the protection against severe hematogenous forms of tuberculosis, vaccination lowers the risk of infection with Mycobacterium tuberculosis. Primary and acquired immunodeficiency, including immunity disorders associated with an ongoing treatment, are contraindications to BCG vaccination. The most common adverse effects following BCG vaccination are reactions at the site of injection and in regional lymph nodes, which usually does not require treatment. Methods of tuberculosis prevention, particularly recommended in low-incidence countries, include: diagnostic investigations of patients who had contacts with pulmonary tuberculosis as well as an active detection and treatment of latent Mycobacterium tuberculosis infection. Latent tuberculosis infection can be identified on the basis of positive results of the tuberculin skin test or interferon-gamma release assays after the active disease has been ruled out. This condition does require prophylactic treatment.
Keywords: BCG vaccination; tuberculosis contact investigation; latent tuberculosis infection BCG vaccination; tuberculosis contact investigation; latent tuberculosis infection

Share and Cite

MDPI and ACS Style

Bielecka, T.; Augustynowicz-Kopeć, E.; Gonerko, P.; Gruszczyński, P.; Korzeniewska-Koseła, M.; Krasińska, M.; Krenke, K.; Lange, J.; Pankowska, A.; Popielarz, M.; et al. Recommendations for the Management of Tuberculosis in Children—KOMPASS TB. Part 1: Tuberculosis Prevention. Adv. Respir. Med. 2018, 86, 149-157. https://doi.org/10.5603/ARM.2018.0023

AMA Style

Bielecka T, Augustynowicz-Kopeć E, Gonerko P, Gruszczyński P, Korzeniewska-Koseła M, Krasińska M, Krenke K, Lange J, Pankowska A, Popielarz M, et al. Recommendations for the Management of Tuberculosis in Children—KOMPASS TB. Part 1: Tuberculosis Prevention. Advances in Respiratory Medicine. 2018; 86(3):149-157. https://doi.org/10.5603/ARM.2018.0023

Chicago/Turabian Style

Bielecka, Teresa, Ewa Augustynowicz-Kopeć, Paweł Gonerko, Paweł Gruszczyński, Maria Korzeniewska-Koseła, Maria Krasińska, Katarzyna Krenke, Joanna Lange, Anna Pankowska, Marek Popielarz, and et al. 2018. "Recommendations for the Management of Tuberculosis in Children—KOMPASS TB. Part 1: Tuberculosis Prevention" Advances in Respiratory Medicine 86, no. 3: 149-157. https://doi.org/10.5603/ARM.2018.0023

Article Metrics

Back to TopTop